All In Biotech

Free tool

FAERS Monitor: Caplyta

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 209500 or its brand name (Caplyta, Lumateperone Tosylate). Reports on generic versions are filed under their own applications.

Reports

7,706

Serious

2,180

28% of reports

Hospitalization

616

Death reported

65

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • dizziness754
  • nausea581
  • headache523
  • somnolence448
  • off label use407
  • drug ineffective357
  • mania315
  • anxiety308
  • sedation292
  • feeling abnormal291
  • insomnia279
  • fatigue275
  • vomiting257
  • suicidal ideation244
  • burning sensation225

Reports by year received

View as table
YearReports
20181
20191
2020170
2021363
2022980
2023622
20241,997
20251,611
20261,961

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,046,453 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
maniaSignal31553.347.815,806
sedationSignal29230.827.58,296
burning sensationSignal2258.87.71,544
suicidal ideationSignal2447.36.41,321
somnolenceSignal4486.15.61,912
dizzinessSignal7544.13.91,827
feeling abnormalSignal2913.33.0474
anxietySignal3083.02.6402
insomniaSignal2792.92.5340
headacheSignal5232.32.1385
nauseaSignal5812.01.9303
vomiting2571.51.342
off label use4071.31.224
fatigue2751.00.90
drug ineffective3570.70.735

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.